Rick,
Your "...no question too dumb..." post could not have come at a more opportune time for me. <g>
In that spirit: What do you, or other thread participants, think of Maxim Pharmaceuticals (MMP)? Their lead product, Maxamine, in combination with IL-2, is currently in PIII for acute myelogenous leukemia and malignant melanoma, and in PI/II for several other indications, including renal cell cancer and HVC (here, I believe, in combination with INF-alpha.) (It could also have applications in the large market cancers, lung and prostate.) AML PII results (length of remissions) look very impressive (at least intuitively; I wasn't able to find or calculate a p-value.) Here is the press release summary: biz.yahoo.com
The MMP website, maxim.com, provides a very general (much too general, really) overview.
Insiders, it should be noted, have been selling: biz.yahoo.com
One final note: MMP's cash position might be of some concern, unless they find a corporate partner, and relatively soon. Also, MMP's price/book is approx. 4-5, which might make it a tad rich for this thread.
Thanks, as always,
RB
|
